Codon

JULY 28, 2025

Researchers have identified nearly 10,000 monogenic diseases , or conditions caused by errors in a single gene. Fortunately, as readily as these diseases are discovered and characterized, so too are many of their cures. Fortunately, as readily as these diseases are discovered and characterized, so too are many of their cures.

Immune Response

Codon

NOVEMBER 3, 2024

Physicians working in the early 20th century had little choice but to treat the world’s most rampant infectious disease with methods such as these. But even now, more than a century later, TB remains the deadliest infectious disease on Earth, killing about 1.2 tuberculosis , the same immune cells cross-react with the pathogen.

Vaccine

Broad Institute

JUNE 25, 2025

Related news Single-cell analysis of Crohn’s disease reveals a detailed picture of inflammation in the gut Up to half of patients with Crohn’s disease, an inflammatory bowel disease, develop a complication called fibrosis, where the gut becomes scarred and obstructed, causing pain and bloating.

Disease

Perficient: Drug Development

APRIL 15, 2025

Defining Long COVID: Clinical Criteria and Diagnostic Challenges Long COVID, as defined by the US Department of Health and Human Services, encompasses signs, symptoms, and conditions present for a minimum of four weeks after initial SARS-CoV-2 infection.

Immune Response

Drug Target Review

SEPTEMBER 5, 2023

By employing a mouse model of Parkinson’s disease, the researchers have illuminated a surprising revelation: it’s the border-associated macrophages (BAMs), not the microglia, that steer the neuroinflammatory response within the brain. However, identifying the precise cells presenting the antigens remained elusive.

Disease

Drug Target Review

AUGUST 11, 2023

1 The study reveals a novel bioinformatic approach and tool that holds the potential to empower researchers in designing vaccines capable of inducing a stronger immune response. By selecting specific segments of proteins that elicit robust immune reactions, these vaccines could offer enhanced protection against diseases.

Vaccine

The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. “In Induction of innate immunity was investigated via specific cytokine markers.

Immune Response

Drug Target Review

SEPTEMBER 9, 2024

functions to reset the immune system and potentially provide remission for allergic diseases? 1104 acts upstream in the inflammatory response, targeting one of the first key players: antigen-presenting cells (APCs). In allergic diseases, APCs identify and present unknown antigens to the immune system.

Disease

Drug Target Review

JANUARY 2, 2024

In research published in Scientific Reports , 1 investigators focused on mesenchymal stem cells (MSCs), known for their potential in treating cell defects and regulating immune responses. We are studying the placement of organelles within cells and how they communicate to help better treat disease,” said Coskun.

RNA

Chemical Biology and Drug Design

JANUARY 29, 2024

sPLA 2 inhibitors have been developed for the treatment of inflammatory and other conditions such as cardiovascular disease, arteriosclerosis and rheumatoid arthritis. Besides their roles in the degradation of phospholipids, these enzymes also play an important role in the immune response by promoting inflammation.

Small Molecule

Drug Target Review

NOVEMBER 24, 2023

2 Previously, La-Beck’s research has shown that liposomes made of phospholipids and cholesterol, like those used in patients, doubled tumour size in mice by suppressing their immune response in some tumours. Macrophages were detected as the cells responsible for these negative effects.

Immune Response

Drug Target Review

DECEMBER 13, 2023

This is likely indicative of the heterogeneous nature of the disorder, and it is this complexity and diversity of clinical presentation and effects across multiple organ systems, that has made efforts to identify genetic risk factors using traditional genomic analysis approaches extremely challenging.

Bioinformatics

Drug Target Review

OCTOBER 19, 2023

A potential game-changer in medicine The implications of this research are vast, potentially transforming the way we treat a variety of diseases involving both the immune and nervous systems. In the absence of IL-31, these nerve cells failed to control the immune system, leading to unchecked inflammation.

Immune Response

SugarCone Biotech

JUNE 10, 2024

Targeting 4-1BB remained of interest to the immuno-oncology field as cell culture experiments and tumor models in mice suggested that robust anti-tumor immune responses could be triggered by anti-4-1BB antibody therapies. This is the T cell type most closely associated with anti-tumor immune responses.

Immune Response

Drug Target Review

SEPTEMBER 11, 2023

While the concept of removing mucins from cancer cells seems promising, mucins are present in various forms on all mammalian cells. Their findings, published in Nature Biotechnology, have broad applications as mucins are associated with many diseases, including cystic fibrosis, respiratory diseases, and viruses.

Immune Response

Drug Target Review

DECEMBER 27, 2023

This interaction inhibits inflammation and immune activation, and in particular prevents macrophages from phagocytosing and destroying cancer cells. By blocking CD24 with an antibody drug, our goal is to powerfully reactivate the anti-cancer immune response and drive therapeutic efficacy.

Immune Response

DrugBank

MARCH 12, 2025

However, mRNA technology is not limited to infectious diseases. This unique mechanism has enabled scientists to rethink how they tackle diseases, paving the way for advancements in oncology, genetic disorders, and regenerative medicine. 

Vaccine

The Pharma Data

OCTOBER 14, 2021

Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). Using data from the MS PATHS network in the U.S.,

Vaccine

The Pharma Data

NOVEMBER 18, 2020

Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort. These results will be presented by the lead investigators of OBI Pharma’s novel anti-Globo H therapeutic cancer vaccine, OBI-833. ” Presentation number: 397P / Poster: ID 680.

Vaccine

Drug Target Review

JUNE 9, 2023

Neoantigen-directed T-cell therapy is a potentially powerful approach that harnesses a patient’s own immune system to fight cancer. One aspect of the collaboration focuses on screening and identification of therapeutic T-cell receptors (TCRs) to target a common shared neoantigen present in many cancer patients.

Treatment

PLOS: DNA Science

OCTOBER 19, 2023

Also recently, FDA’s Cellular, Tissue, and Gene Therapies Advisory Committe turned down a stem cell treatment for amyotrophic lateral sclerosis, aka ALS, Lou Gehrig’s disease, or motor neuron disease. ALS is a disease of adulthood, beginning typically between 40 and 70 years of age. Most ALS cases are sporadic.

Therapies

The Pharma Data

DECEMBER 16, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 GAITHERSBURG, Md., 16, 2020 (GLOBE NEWSWIRE) — Novavax , Inc. About Novavax. Novavax, Inc.?(Nasdaq:

Vaccine

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies

The Pharma Data

DECEMBER 8, 2020

Overall, the vaccine protected against symptomatic disease in 70% of cases, according to a team led by researchers from Oxford University in England. ” Previous clinical trials of the vaccine had found that the vaccine triggers antibody and T-cell immune responses, and is safe in people aged 18 and older. . TUESDAY, Dec.

Vaccine

The Pharma Data

FEBRUARY 18, 2022

Findings show that the percentage of patients achieving clinical remission, clinical response, endoscopic improvement and corticosteroid-free remission was maintained through Week 142. Additional Bristol Myers Squibb-sponsored abstracts presented at the ECCO 2022 Congress can be accessed online here. About Ulcerative Colitis.

Clinical Trials

Drug Target Review

FEBRUARY 28, 2024

Belying that earlier assumption, multiple studies have now shown γδ T cells to be very powerful components of the immune system that sit at the nexus of innate and adaptive immunity. Human γδ TCR repertoires in health and disease. gammadelta T cells link innate and adaptive immune responses. Cells 9(40):800 (2020).

Therapies

The Pharma Data

JUNE 25, 2021

Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% 100) against moderate or severe disease. It was generally well-tolerated and elicited robust antibody response in Phase 1/2 clinical testing.

Vaccine

Drug Target Review

SEPTEMBER 8, 2023

Remarkably, these findings propose that the presence of a cytoplasmic version of RARα is indispensable for T cells to initiate their defence against diseases. Importantly, this phenomenon’s silver lining is that RA’s interference with cytoplasmic RARα curbs the T cell’s inflammatory response.

Regulations

The Pharma Data

OCTOBER 19, 2020

Immune responses following vaccination with PNEUMOVAX 23 (month 13) were comparable in both vaccination groups for the 15 serotypes in V114. Results from both studies are based on opsonophagocytic activity (OPA) responses – a measure of vaccine-induced functional antibodies. among adults 65 years of age or older.

Vaccine

The Pharma Data

JANUARY 25, 2021

25, 2021 — Giving melanoma patients a “personalized” vaccine can prompt an anti-tumor immune response that lasts for years, an early study finds. But it builds on earlier work showing it is possible to spur the immune system to respond to an individual’s unique tumor. MONDAY, Jan. 21 in Nature Medicine.

Vaccine

The Pharma Data

JUNE 12, 2025

The data, stemming from Cohort B of the study (NCT05162586) , were presented in a late-breaking oral presentation during the 2025 European Congress of Rheumatology (EULAR) in Barcelona (Abstract #LB0004). Eric Morand, from Monash University and Monash Health.

Immune Response

The Pharma Data

JUNE 25, 2021

In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria.

Vaccine

The Pharma Data

DECEMBER 13, 2020

SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic designed to activate the STING pathway in the tumor microenvironment in order to upregulate the patient’s immune response. Synlogic’s President and Chief Executive Officer.

Immune Response

The Pharma Data

APRIL 8, 2021

Early clinical results are consistent with preclinical studies and suggest THOR-707 (SAR444245) may promote an anti-tumor immune response without alpha-mediated side effects, both alone and in combination with anti-PD-1. We will continue to explore the molecule’s potential for best-in-disease combinations.”.

Immune Response

The Pharma Data

SEPTEMBER 30, 2021

A consistent finding from the observational studies is that vaccines remain highly effective against severe disease, including that from all the most viral variants. Across all vaccine types and variants, vaccine efficacy is bigger against severe disease than against mild disease. The Lancet, 2021. Source link: [link].

Vaccine

The Pharma Data

JULY 6, 2021

New research from first-in-class marketed and investigational therapies in hemophilia, immune thrombocytopenia and acquired thrombotic thrombocytopenic purpura will be presented. Oral presentation. Interim Phase 1/2 study data will be presented at ISTH. Oral Presentation. ePoster Abstract # OC48.2 Abstract # OC72.2

Therapies

Drug Target Review

APRIL 3, 2024

Making a little tangle of DNA visible to the eye and understanding that this is the basis of complex organisms, which might be altered in disease, was the defining moment for my future path in life sciences. In this regard, AI presents itself as a valuable ally, offering the potential to bolster our endeavours and ensure successful outcomes.

Science